A team of researchers at the Ragon Institute of MGH, MIT and Harvard and the Broad Institute of MIT And Harvard have recently identified human genes that could be the key to a gene therapy-based HIV treatment.
17 January 2017 | BETA blog
In 2017, a key focus in the field of HIV will be investigating new ways to tackle persistence via interactions and synergies with other fields such as cancer research and immune-based therapies. This will take centre stage when the scientific community convenes in July 2017 at the IAS HIV Cure & Cancer Forum and the 9th IAS Conference on HIV Science (IAS 2017).
16 January 2017 | International AIDS Society
Gilead Sciences, Inc. today announced the recipients of its HIV cure grants program, a fund totaling more than $22 million, which will support 12 new HIV cure research projects. These projects will be conducted by leading academic institutions, non-profit organizations and community groups from around the world, focusing on three key areas: translational research, efficacy studies in animal models and community perspectives of HIV cure.
10 January 2017 | Gilead press release
What’s going on in HIV cure research? Is it ethical to take people off of HIV antiretrovirals if they participate in HIV cure research? These were some of the questions that lead researchers who are part of the amfAR Institute for HIV Cure Research at UCSF tackled at a forum on World AIDS Day this year.
22 December 2016 | BETA blog
Scientists from the National Institutes of Health have identified an antibody from an HIV-infected person that potently neutralized 98 percent of HIV isolates tested, including 16 of 20 strains resistant to other antibodies of the same class. The remarkable breadth and potency of this antibody, named N6, make it an attractive candidate for further development to potentially treat or prevent HIV infection, say the researchers.
17 November 2016 | National Institute of Allergy and Infectious Diseases
An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.
10 November 2016 | Reuters
A tabletop device that enables medical staff to genetically manipulate a patient’s blood to deliver potential new therapies for cancer, HIV and other diseases would eliminate the need for multimillion-dollar “clean rooms,” making gene therapy more possible for even the poorest of countries.
21 October 2016 | Fred Hutchinson Cancer Research Center
UCSF researchers have found in autopsy tissue samples of patients treated with antiretrovirals that the virus evolved and migrated among tissues similar to the way it did in patients who had never received antiretroviral treatment, despite the fact that the treated patients had undetectable levels of virus in their blood.
20 October 2016 | Eurekalert Inf Dis
In Science today, a team led by immunologist Aftab Ansari of Emory University School of Medicine in Atlanta describes infecting eight monkeys with SIV, the simian version of HIV, treating them with ARVs, and then infusing them with an antibody similar to an approved drug for Crohn's disease and ulcerative colitis that targets a receptor on immune cell surfaces known as α4ß7.
14 October 2016 | Science
A clinical trial in monkeys found that by augmenting the standard HIV treatment with an antibody developed in the lab, the animals were able to enter a state of sustained remission, according to a report in Friday’s edition of the journal Science.
14 October 2016 | Los Angeles Times